Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
High-Tech Contact Lenses May Replace Smart Phones
When Alexander Graham Bell brought us the revolutionary first ever telephone back in 1876, the world was changed forever. Ever since then, telephonic devices have been a mainstay of the modern world; an essential part of our everyday lives. Of…
Ximluci Receives Marketing Approval in the UK
STADA Arzneimittel AG and Xbrane Biopharma AB announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ximluci® (ranibizumab), a biosimilar of Lucentis®. STADA plans to launch Ximluci in the United Kingdom in 2023. Xbrane’s contribution to…
Viatris Closes Oyster Point, Famy Life Acquisitions
Viatris announced the completion of its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. On November 7, the purchase was originally announced. Jeffrey Nau, PhD, MMS, former CEO of Oyster Point…
Sifi and Avanzanite Sign License Agreement
Italy-based Sifi formed a collaboration with Avanzanite Bioscience, a Dutch specialty pharmaceutical business, to commercialize and distribute Akantior (polihexanide) exclusively in 26 European Economic Area and Swiss countries. Sifi will manage all ongoing regulatory activities under the terms of the…
Elios Tech Now Registered in the UK
Elios Vision stated that its Elios technology, which is used to treat glaucoma concurrently with cataract surgery, is officially registered in the United Kingdom. The Elios does not require an implant and is designed to provide long-lasting results that may…
Harrow Now Offering Fortisite Formulations for In-Office Use
Harrow announced the availability of Fortisite (compounded Tobramycin 1.5% + Vancomycin 5%) for in-office use from its FDA-registered and FDA-inspected ImprimisRx 503B outsourcing facility. Fortisite formulations are high-concentration, refrigeration-stable, fortified antibiotic formulations in solution that are patent-pending. According to Harrow,…
RCA Acquires Retina Group of New England
Retina Consultants of America (RCA) announced it has added Retina Group of New England (RGNE) into its network of physicians. With this expansion, RCA will enter its 30th partnership and open operations in Connecticut, expanding its presence to 20 states…
FDA Greenlights Genentech’s Vabysmo | OBN
The FDA has approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), marking the first bispecific antibody approved for the eye. Vabysmo is also the first and only FDA-approved injectable eye…
Amgen to Buy Horizon Therapeutics
Amgen announced it is acquiring rare disease drug company Horizon Therapeutics, maker of eye disease drugs Tepezza and Uplizna, in a deal valued at $27.8 billion. The company will pay $116.50 in cash per share, a premium of 19.7% to…
Announcing Jacque Duncan, MD, as Chair of the UCSF Department of Ophthalmology – UCSF School of Medicine
Announcing Jacque Duncan, MD, as Chair of the UCSF Department of Ophthalmology UCSF School of Medicine Source: Author: | Date: 2022-11-30 08:00:00 Source: Author: | Date: 2022-11-30 08:00:00